Revenue grew 24% year-over-year in Q2 2025, with strong EBITDA margin and expanding international presence. Major orders in healthcare and recycling, plus a strategic entry into pharmaceuticals, support continued growth. Equity ratio remains high at 79%.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.